Cytomx Therapeutics Inc (CTMX) - News Archive

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a pioneering company in the sphere of masked, conditionally activated biologic therapeutics, has recently achieved significant milestones that underscore its innovative prowess...

CSIMarket.com reports significant advancement in cancer therapeutics with CytomX Therapeutics confirming critical initial Phase 1a dose escalation data for the monotherapy CX-904, an EGFRxCD3 PROBODY T-cell engager. Thi...

CSIMarket.com CytomX Therapeutics, a leading biopharmaceutical company focused on developing innovative antibody-based therapies, recently announced a clinical collaboration with Merck, known as MSD outside the United S...

San Francisco-based biopharmaceutical company CytomX Therapeutics has proudly announced their nomination of the second clinical candidate in its Broad PROBODY T-Cell Engaging Bispecific (TCB) collaboration with Astellas...

In a significant development, CytomX Therapeutics recently announced the initiation of a Good Laboratory Practice (GLP) toxicology study for its first clinical candidate in the PROBODYT-Cell Engaging Bispecific (TCB) co...

CytomX Therapeutics, a renowned biotechnology company specializing in developing transformative antibody-drug conjugates, has recently announced its 2024 priorities and milestones. By aligning their focus on cutting-edg...